Mizuho reiterated their buy rating on shares of Amedisys Inc (NASDAQ:AMED) in a report issued on Wednesday morning, Marketbeat reports. The brokerage currently has a $65.00 price objective on the health services provider’s stock, up from their previous price objective of $55.00.

Several other brokerages have also commented on AMED. BidaskClub lowered Amedisys from a strong-buy rating to a buy rating in a research note on Wednesday, July 12th. Robert W. Baird reaffirmed a hold rating and issued a $50.00 price target on shares of Amedisys in a research note on Wednesday, October 4th. Oppenheimer Holdings, Inc. reaffirmed a buy rating and issued a $60.00 price target on shares of Amedisys in a research note on Friday, September 15th. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $60.00 price target on shares of Amedisys in a research note on Monday, October 9th. Finally, Royal Bank Of Canada reaffirmed a hold rating on shares of Amedisys in a research note on Monday, October 23rd. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Amedisys has an average rating of Hold and a consensus price target of $61.00.

Shares of Amedisys (NASDAQ:AMED) traded down $0.14 during trading on Wednesday, hitting $56.25. The stock had a trading volume of 310,900 shares, compared to its average volume of 485,523. Amedisys has a twelve month low of $38.00 and a twelve month high of $65.91. The firm has a market cap of $1,908.96, a price-to-earnings ratio of 26.91, a PEG ratio of 1.37 and a beta of 0.68. The company has a current ratio of 1.33, a quick ratio of 1.21 and a debt-to-equity ratio of 0.16.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.02. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The business had revenue of $380.20 million for the quarter, compared to analyst estimates of $384.59 million. During the same quarter in the prior year, the company posted $0.36 EPS. The company’s quarterly revenue was up 5.1% on a year-over-year basis. research analysts expect that Amedisys will post 2.22 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Amedisys’ (AMED) “Buy” Rating Reiterated at Mizuho” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/amedisys-amed-buy-rating-reiterated-at-mizuho/1698609.html.

A number of hedge funds and other institutional investors have recently modified their holdings of AMED. UBS Asset Management Americas Inc. increased its holdings in Amedisys by 140.0% during the 1st quarter. UBS Asset Management Americas Inc. now owns 11,760 shares of the health services provider’s stock worth $601,000 after purchasing an additional 6,861 shares during the period. Teachers Advisors LLC increased its holdings in Amedisys by 1.5% during the 1st quarter. Teachers Advisors LLC now owns 77,481 shares of the health services provider’s stock worth $3,959,000 after purchasing an additional 1,144 shares during the period. Legal & General Group Plc increased its holdings in Amedisys by 3.6% during the 1st quarter. Legal & General Group Plc now owns 51,887 shares of the health services provider’s stock worth $2,652,000 after purchasing an additional 1,825 shares during the period. Thrivent Financial For Lutherans increased its holdings in Amedisys by 3.8% during the 1st quarter. Thrivent Financial For Lutherans now owns 15,703 shares of the health services provider’s stock worth $802,000 after purchasing an additional 570 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Amedisys by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 2,369,678 shares of the health services provider’s stock worth $121,067,000 after purchasing an additional 63,238 shares during the period. Institutional investors own 96.36% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.